Skip to main content
WeightCited

Metabolic Syndrome
Metabolic Syndrome

Tỷ lệ mắc: 34.7% of US adults (NHANES); increases with age: 50% in those >60 years

<\/script>\n
`; }, get iframeSnippet() { const domain = 'weightcited.com'; const params = 'condition\u003Dmetabolic\u002Dsyndrome'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

Evidence-Ranked Ingredients

Thành phần Xếp hạng Nghiên cứu Xu hướng
Berberine A 12 Positive Xem →
Omega-3 B 44 Positive Xem →
Magnesium B 32 Positive Xem →
Taurine B 25 Positive Xem →

About

{# Filter order is load-bearing: escape (untrusted text) -> linebreaks (paragraphs) -> paper anchors (internal /papers/ links) -> glossary (never links inside an existing ). #}

Metabolic syndrome is a diagnostic cluster rather than a single disease: any three of five interconnected abnormalities, namely abdominal obesity, high triglycerides, reduced HDL cholesterol, raised blood pressure, and raised fasting glucose. NHANES data place it in 34.7 percent of US adults and in about half of those over 60. Insulin resistance underlies most of the cluster, which is why the ingredient set graded against it overlaps heavily with the set graded against insulin resistance itself. Four ingredients carry grades here, drawn from 113 studies and roughly 7,450 participants.

Berberine holds Grade A on 12 studies and 1,068 participants. Recent mechanistic work has linked its metabolic effects to the composition of the gut microbiome, reporting increased abundance of Akkermansia muciniphila in a model of metabolic dysfunction-associated steatohepatitis [1], and combination work with evodiamine has examined hepatic outcomes in diet-induced fatty liver disease [2]. Both are preclinical, and the distance between a rodent liver model and a clinical endpoint is considerable.

Omega-3 fatty acids carry the largest study base in the set, 44 trials and 3,000 participants, at Grade B. The mechanistic literature is comparatively specific here: omega-3 intake alters adipose tissue function in obesity and metabolic syndrome [3], and the abnormal lipoprotein oxylipin profile characteristic of the syndrome is partially corrected by supplementation [4]. Triglyceride reduction remains the most consistently reported clinical effect.

Magnesium follows with 32 studies and 2,382 participants and taurine with 25 studies and 1,000 participants, both at Grade B. Magnesium status relates to several components of the cluster at once, including blood pressure and glucose handling, while taurine has been studied mainly against blood pressure and lipid endpoints. Neither is positioned as a single-agent answer to a definition with five components.

The syndrome's drivers include visceral adiposity, physical inactivity, aging, pro-inflammatory dietary patterns, sleep apnea, polycystic ovary syndrome, and genetic predisposition; a 2023 review adds psychological stress and depression by way of a chronic inflammatory pathway [5]. Two limits bound the evidence above. Trials typically report a single component of the cluster, most often triglycerides or fasting glucose, so an effect on the full diagnostic definition is rarely demonstrated. And because berberine and magnesium interact with glucose-lowering and antihypertensive agents, and omega-3 with anticoagulants, supplement decisions here sit properly with the clinician managing the underlying components rather than with the individual components alone.

Common Symptoms

Central obesity Elevated blood pressure Elevated fasting glucose High triglycerides Low HDL cholesterol Fatigue Increased thirst/urination

Risk Factors

  • Visceral adiposity
  • Insulin resistance
  • Physical inactivity
  • Aging
  • Genetic predisposition
  • Pro-inflammatory diet
  • Sleep apnea
  • Polycystic ovary syndrome

Frequently Asked Questions

What supplements may help with Metabolic Syndrome?
Based on peer-reviewed research, supplements with the strongest evidence for Metabolic Syndrome include Berberine, Omega-3, Magnesium, Taurine. These have earned Grade A or B ratings from our analysis of clinical studies. Always consult your healthcare provider before starting any supplement.
How is the evidence for Metabolic Syndrome supplements graded?
We grade supplements on an A-F scale based on clinical study quality, consistency of results, sample sizes, and study design. Grade A indicates strong evidence from multiple clinical trials, while Grade D indicates preliminary evidence requiring further research.
How many studies on Metabolic Syndrome supplements have been reviewed?
Our evidence grades for Metabolic Syndrome are based on a total of 113 peer-reviewed studies across 4 ingredients. Studies are sourced from PubMed and include randomized controlled trials, meta-analyses, and other clinical research.
What are common symptoms of Metabolic Syndrome?
Common symptoms associated with Metabolic Syndrome include Central obesity, Elevated blood pressure, Elevated fasting glucose, High triglycerides, Low HDL cholesterol. If you are experiencing these symptoms, consult a healthcare professional for proper diagnosis and treatment options.

References

  1. 1. Berberine alleviates metabolic dysfunction-associated steatohepatitis by enhancing the abundance of Akkermansia muciniphila. The Journal of nutritional biochemistry, 2025 PMID 40816629
  2. 2. The combination of berberine and evodiamine ameliorates high-fat diet-induced non-alcoholic fatty liver disease associated with modulation of gut microbiota in rats. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, 2022 PMID 35584453
  3. 3. Omega-3 fatty acids and adipose tissue function in obesity and metabolic syndrome. Prostaglandins & other lipid mediators, 2015 PMID 26219838
  4. 4. Abnormal lipoprotein oxylipins in metabolic syndrome and partial correction by omega-3 fatty acids. Prostaglandins, leukotrienes, and essential fatty acids, 2018 PMID 29413356
  5. 5. A review on linking stress, depression, and insulin resistance via low-grade chronic inflammation. Biochemistry and biophysics reports, 2023 PMID 37965066

Các tình trạng có chung thành phần được nghiên cứu

Tuyên bố miễn trừ FDA: Các tuyên bố này chưa được Cục Quản lý Thực phẩm và Dược phẩm (FDA) đánh giá. Các sản phẩm và thông tin trên trang web này không nhằm mục đích chẩn đoán, điều trị, chữa bệnh hoặc phòng ngừa bất kỳ bệnh nào. Xếp hạng bằng chứng được trình bày dựa trên phân tích của chúng tôi về nghiên cứu đã bình duyệt được công bố và không cấu thành tư vấn y khoa. Luôn tham khảo ý kiến chuyên gia y tế trước khi bắt đầu bất kỳ chế độ thực phẩm chức năng nào.